

European Journal of Preventive Cardiology

Light to moderate coffee consumption is associated with lower risk of death: a UK Biobank study --Manuscript Draft--

Manuscript Number:	EJPC-D-21-01678R1
Full Title:	Light to moderate coffee consumption is associated with lower risk of death: a UK Biobank study
Article Type:	Full Research Paper
Section/Category:	Nutrition/Obesity (diet, alcohol)
Keywords:	Cardiac magnetic resonance; Cardiovascular health; Coffee consumption
Corresponding Author:	Pál Maurovich-Horvat Semmelweis University: Semmelweis Egyetem HUNGARY
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	Semmelweis University: Semmelweis Egyetem
Corresponding Author's Secondary Institution:	
First Author:	Judit Simon
First Author Secondary Information:	
Order of Authors:	Judit Simon Kenneth Fung Zahra Raisi-Estabragh Nay Aung Mohammed Y Khanji Márton Kolossváry Béla Merkely Patricia B Munroe Nicolas C Harvey Stefan K Piechnik Stefan Neubauer Steffen E Petersen Pál Maurovich-Horvat
Order of Authors Secondary Information:	
Manuscript Region of Origin:	HUNGARY
Abstract:	<p>Aims</p> <p>To study the association of daily coffee consumption with all-cause and cardiovascular (CV) mortality and major CV outcomes. In a subgroup of participants who underwent cardiovascular magnetic resonance (CMR) imaging, we evaluated the association between regular coffee intake and cardiac structure and function.</p> <p>Methods</p> <p>UK Biobank participants without clinically manifested heart disease at the time of</p>

recruitment were included. Regular coffee intake was categorized into 3 groups: zero, light-to-moderate (0.5-3 cups/day) and high (>3 cups/day). In the multivariate analysis, we adjusted for the main CV risk factors.

Results

We included 468,629 individuals (56.2±8.1 years, 44.2% male), 22.1% did not consume coffee on a regular basis, 58.4% had 0.5-3 cups per day and 19.5% had >3 cups per day. Compared to non-coffee drinkers, light-to-moderate (0.5-3 cups per day) coffee drinking was associated with lower risk of all-cause mortality (multivariate HR=0.88, 95%CI:0.83-0.92; p<0.001) and CV mortality (multivariate HR=0.83, 95%CI:0.74-0.94; p=0.006), and incident stroke (multivariate HR=0.79, 95%CI:0.63-0.99 p=0.037) after a median follow-up of 11 years. CMR data were available in 30,650 participants. Both light-to-moderate and high coffee consuming categories were associated with dose-dependent increased left and right ventricular end-diastolic, end-systolic and stroke volumes, as well as greater left ventricular mass.

Conclusion

Coffee consumption of up to 3 cups per day was associated with favorable CV outcomes. Regular coffee consumption was also associated with a likely healthy pattern of CMR metrics in keeping with the reverse of age-related cardiac alterations.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Title

Light to moderate coffee consumption is associated with lower risk of death: a UK Biobank study

Brief title

Regular coffee consumption reduces risk of death

Authors

Judit Simon MD^{a,b}, Kenneth Fung MD^{c,d}, Zahra Raisi-Estabragh MD^{c,d}, Nay Aung MD^{c,d}, Mohammed Y Khanji MD^{c,d,e}, Márton Kolossváry MD^a, Béla Merkely MD^a, Patricia B Munroe MD^c, Nicholas C Harvey MD^f, Stefan K Piechnik MD^g, Stefan Neubauer MD^g, Steffen E Petersen MD^{c,d*}, Pál Maurovich-Horvat MD^{a,b*}

*Contributed equally to this work

Affiliations

^aMTA-SE Cardiovascular Imaging Research Group, Semmelweis University, Budapest, Hungary

^bMedical Imaging Centre, Semmelweis University, Budapest, Hungary

^cWilliam Harvey Research Institute, NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, United Kingdom

^dBarts Heart Centre, St Bartholomew's Hospital, Barts NHS Trust, West Smithfield, London, United Kingdom

^eNewham University Hospital, Glen Road, Plaistow, Barts Health NHS Trust, London, United Kingdom

^fMRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

[§]National Institute for Health Research, Oxford Biomedical Research Centre, Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom

Short running head

Regular coffee consumption and cardiovascular health

Word count

4297

Acknowledgement

This study was conducted using the UK Biobank resource under access application 2964.

Funding

P.B.M and S.E.P acknowledge support from the National Institute for Health Research (NIHR) Barts Biomedical Research Centre. S.E.P. acknowledges support from the ‘SmartHeart’ EPSRC programme grant (www.nihr.ac.uk; EP/P001009/1) and also from the CAP-AI programme, London’s first AI enabling programme focused on stimulating growth in the capital’s AI Sector. CAP-AI is led by Capital Enterprise in partnership with Barts Health NHS Trust and Digital Catapult and is funded by the European Regional Development Fund and Barts Charity. S.E.P. and S.N. acknowledge the British Heart Foundation for funding the manual analysis to create a cardiovascular magnetic resonance imaging reference standard for the UK Biobank imaging resource in 5000 CMR scans (www.bhf.org.uk; PG/14/89/31194). S.N and SKP supported by the Oxford NIHR Biomedical Research Centre and S.N. by the Oxford British Heart Foundation Centre of Research Excellence. N.A. recognize the National Institute for Health Research (NIHR) Integrated Academic Training programme which supports their Academic Clinical Lectureship posts. N.C.H acknowledges support from the UK Medical Research Council (MRC #405050259 and #U105960371), NIHR Southampton Biomedical Research Centre, University of Southampton, and University Hospital Southampton. Z.R.E was

1 supported by a British Heart Foundation Clinical Research Training Fellowship
2 (FS/17/81/33318). Project no. NVKP_16-1–2016-0017 ('National Heart Program') has been
3
4 implemented with the support provided from the National Research, Development and
5
6 Innovation Fund of Hungary, financed under the NVKP_16 funding scheme. The research was
7
8 financed by the Thematic Excellence Programme (2020-4.1.1.-TKP2020) of the Ministry for
9
10 Innovation and Technology in Hungary, within the framework of the Therapeutic Development
11
12 and Bioimaging thematic programmes of the Semmelweis University.
13
14
15

16 **Corresponding author**

17 Pál Maurovich-Horvat MD PhD MPH DSc

18
19 MTA-SE Cardiovascular Imaging Research Group, Semmelweis University, Budapest,
20
21
22 Hungary
23
24

25
26 Address: H-1082 Budapest, Üllői út 78. Hungary

27
28 Email: maurovich-horvat.pal@med.semmelweis-univ.hu

29
30 Phone: +36-1-210-0300/53312

31
32 Fax: +36-1-459-1500/53171

33
34
35 Twitter: @PalMaurovich

36
37
38 Tweet: "Light to moderate coffee consumption is associated with lower risk of death: a UK
39
40
41 Biobank study" #Coffee #CardiovascularHealth #Prevention
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Aims

To study the association of daily coffee consumption with all-cause and cardiovascular (CV) mortality and major CV outcomes. In a subgroup of participants who underwent cardiovascular magnetic resonance (CMR) imaging, we evaluated the association between regular coffee intake and cardiac structure and function.

Methods

UK Biobank participants without clinically manifested heart disease at the time of recruitment were included. Regular coffee intake was categorized into 3 groups: zero, light-to-moderate (0.5-3 cups/day) and high (>3 cups/day). In the multivariate analysis, we adjusted for the main CV risk factors.

Results

We included 468,629 individuals (56.2±8.1 years, 44.2% male), 22.1% did not consume coffee on a regular basis, 58.4% had 0.5-3 cups per day and 19.5% had >3 cups per day. Compared to non-coffee drinkers, light-to-moderate (0.5-3 cups per day) coffee drinking was associated with lower risk of all-cause mortality (multivariate HR=0.88, 95%CI:0.83-0.92; p<0.001) and CV mortality (multivariate HR=0.83, 95%CI:0.74-0.94; p=0.006), and incident stroke (multivariate HR=0.79, 95%CI:0.63-0.99 p=0.037) after a median follow-up of 11 years. CMR data were available in 30,650 participants. Both light-to-moderate and high coffee consuming categories were associated with dose-dependent increased left and right ventricular end-diastolic, end-systolic and stroke volumes, as well as greater left ventricular mass.

Conclusion

Coffee consumption of up to 3 cups per day was associated with favorable CV outcomes. Regular coffee consumption was also associated with a likely healthy pattern of CMR metrics in keeping with the reverse of age-related cardiac alterations.

Keywords

Cardiac magnetic resonance; Cardiovascular health; Coffee consumption

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

1
2 Even though coffee is among the most consumed beverages in the world, little is known about
3
4 the long-term impact of its regular consumption on cardiovascular (CV) health. Besides
5
6 caffeine, it contains many bioactive components such as minerals and antioxidants (1, 2).
7
8 Recent studies have shown that coffee plays a preventive role against cancer, obesity, type 2
9
10 diabetes mellitus, Parkinson's disease and dementia (3-7). However, there are inconsistent
11
12 results regarding its CV effects. Although most studies have found no relationship between
13
14 regular coffee intake and CV disease mortality, some have reported a moderate inverse
15
16 association while others have found an increased risk (8-12).
17
18
19
20

21 Coffee is mainly consumed as ground or instant form, containing different chemical
22
23 compounds. Instant coffee is reported to contain not only more caffeine and antioxidants as
24
25 ground type coffee, but it also has twice as much acrylamide, which was shown to be neurotoxic
26
27 and carcinogenic (13, 14). While several studies have investigated the relationship between
28
29 coffee type and cancer, the association between coffee type and subclinical cardiac alterations
30
31 are unclear (15-17).
32
33
34
35

36 We studied, in the UK Biobank, the association of regular coffee consumption with all-cause
37
38 mortality, CV mortality, and cardiovascular magnetic resonance (CMR) phenotypes. We
39
40 limited to participants without clinically manifested heart disease at the time of recruitment. In
41
42 secondary analyses, we investigated the relationship between consumed coffee type and cardiac
43
44 structural and functional alterations.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2 **Methods**
3

4
5 **Study sample and outcomes**
6

7
8 The UK Biobank is a prospective cohort study which collected questionnaire data, physical
9 measurements and biological samples from over half a million 40-69 year-old individuals in
10 the United Kingdom recruited between 2006 and 2010 (18). Baseline assessment of the
11 participants included detailed assessment of medical history, lifestyle and nutritional habits,
12 physical examination and blood sampling. Exclusion criteria of the current study were refusal
13 to report coffee drinking habits, those who drink >25 cups of coffee per day, presence of heart
14 failure, angina, prior myocardial infarction and stroke at the time of recruitment and refusal to
15 consent. The endpoints of death, stroke and myocardial infarction were derived from Hospital
16 Episode Statistics and death register data. CV mortality was defined as deaths where underlying
17 (primary) causes were related to the circulatory system. Detailed list of causes with number of
18 cases is reported in *Supplementary table 1*. This study was covered by the ethical approval for
19 UK Biobank studies from the National Health Service (NHS) National Research Ethics Service
20 on 17th June 2011 (Ref 11/NW/0382) and extended on 10th May 2016 (Ref 16/NW/0274).
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **Patient and public involvement**
41

42
43 No patients were involved in setting the research question or the outcome measures, nor were
44 they involved in developing plans for design or implementation of the study. No patients were
45 asked to advise on interpretation or writing up of results. There are no plans to disseminate the
46 results of the research to study participants or the relevant patient community.
47
48
49
50
51
52

53 **Cardiovascular measurements**
54

55
56 Arterial stiffness index (ASI) was measured at the baseline visit with finger
57 photoplethysmography with the PulseTrace PCA2 device (CareFusion, San Diego, CA, USA)
58
59
60
61

1 while participants were seated. Readings were taken over 10-15 seconds. A detailed protocol
2 has been described (<https://biobank.ndph.ox.ac.uk/showcase/showcase/docs/Pulsewave.pdf>).
3
4 ASI provides a measure of large artery stiffness, an indicator of arterial health and ischemic
5 risk (19).
6
7

8
9
10 In total, 100,000 participants ~~are being~~were recalled to undergo comprehensive imaging of the
11 brain, heart, whole body, carotid artery, bone and joints. Imaging of the heart ~~is~~was performed
12 by CMR (20). The UK Biobank CMR protocol has been described in detail previously (21, 22).
13
14 Briefly, all examinations were performed on a 1.5 Tesla scanner (MAGNETOM Aera, Syngo
15 Platform VD13A, Siemens Healthcare, Erlangen, Germany). For cardiac function, long-axis
16 cines and a complete short-axis stack of balanced steady-state free precession (bSSFP) cines
17 were acquired covering the left and right ventricle. The manual analysis dataset of 5,065
18 participants was used to develop an automated image analysis pipeline, which has been
19 propagated to the first 32,000 CMR studies (23). Those with heart failure, prior myocardial
20 infarction, stroke and angina at imaging visit were excluded from the CMR subanalysis. We
21 examined left and right ventricular end-diastolic (LVEDV; RVEDV), end-systolic (LVESV;
22 RVESV), and stroke volumes (LVSV; RVSV), left ventricular mass (LVM) and left and right
23 ventricular ejection fractions (LVEF; RVEF).
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 **Measurement of baseline covariates, potential confounders and coffee consumption**

44
45

46 Data regarding coffee consumption were obtained from standardized and validated
47 questionnaires filled in by the study participants at baseline visit. Participants were asked their
48 average coffee intake in the last year: “how many cups of coffee do you drink each day”, as
49 well as the most common type of consumed coffee (decaffeinated, ground, instant or other
50 type). We selected confounders and possible mediators of the relationship between coffee
51 consumption with CV health. These covariates were determined from participant interview or
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 touchscreen questionnaires. The following variables were recorded: age, sex, non-European
2 ethnicities, Townsend deprivation index (a socio-economic measure based on area of
3 residence), weight and height, cardiometabolic comorbidities such as hypertension or diabetes.
4 Moreover, lifestyle factors such as physical activity (expressed as metabolic equivalent (MET)
5 minutes/week), fresh and dried fruit, raw or cooked vegetable intake (portions per day), tea
6 intake (cups per day), alcohol intake frequency (never, special occasions only, 1-3 times per
7 month, 1-2 times per week, 3-4 times per week, and daily or almost daily), meat intake
8 frequency (never, less than once per week, once per week, 2-4 times per week, 5-6 times per
9 week, once or more daily) and smoking status (never smoker and previous or current smoker)
10 were also ascertained. Detailed questions of the UK Biobank questionnaires can be found in
11 UK Biobank Data Showcase (<https://www.ukbiobank.ac.uk/data-showcase/>). Total cholesterol
12 levels were determined with blood biochemistry.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

28 **Data analysis and statistics**

29
30
31
32
33
34 Summary statistics for independent variables were calculated as means and standard deviation
35 (SD) for continuous variables. Categorical variables were expressed as frequencies and
36 percentages. Consistent with previous studies, regular coffee consumption was categorized into
37 3 groups: zero, light-to-moderate (0.5–3 cups/day), and high (>3 cups per day) with the lowest
38 group (zero coffee consumption) used as the reference in the analyses (24). The event-free
39 survival rate was estimated using Kaplan-Meier method and log-rank test was applied for the
40 comparisons between the various coffee intake groups. Cumulative event rates were calculated
41 with event or censoring times measured from the date of baseline visit. For participants without
42 outcome, time-to-event measures were censored at the latest UK Biobank censor dates giving
43 a follow-up duration of 10 to 15 years. To assess the relationship between the amount of coffee
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 intake and CV morbidity and mortality, uni- and multivariable Cox proportional hazard
2 regression models were executed.
3
4

5 We considered two approaches to covariate adjustment. Model 1 was created as a “true
6 confounder model”. In this model, we adjusted for covariates that were considered confounders
7 of the associations of interest, selected based on biological plausibility and existing evidence.
8 The purpose of Model 1 was to quantify the magnitude of the exposure-outcomes associations.
9 Model 2 included adjustment of both true confounders (all covariates in Model 1) and potential
10 mediators. Mediators were considered covariates that may lie on the causal pathway for the
11 association between coffee and CV health. The expectation is that in the presence of significant
12 mediating effect from these covariates, their addition to the model (as in Model 2) would
13 attenuate the magnitude of exposure-outcome associations observed in the true confounder
14 model. The purpose of Model 2 was to explore potential mediating effect from selected
15 cardiometabolic morbidities. Model 1 included coffee consumption categories and the
16 following potential confounders: age, sex, non-European ethnicity, weight and height, smoking
17 status, physical activity, Townsend deprivation index, regular alcohol and meat consumption,
18 tea, cooked and raw fruit and vegetable intake. Model 2 included parameters of Model 1 and
19 the following potential mediators: hypertension, diabetes and cholesterol level.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

43 Associations between regular coffee intake and structural and functional CMR parameters were
44 analyzed using unadjusted and multivariable linear regression analyses using the same models.
45 Definitions for these covariates were previously described (25, 26). In order to assess the
46 association between most common type of consumed coffee and CMR parameters, we ran a
47 subanalysis of decaffeinated, ground, instant or other coffee type. A p-value below 0.05 was
48 considered statistically significant. Statistical analysis was performed using R (version 4.0.2)
49 Statistical Software (27).
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Results

After exclusion, 468,629 individuals were included in this study. At the time of recruitment their mean age was 56.2±8.1 years and 44.2% of the participants were male. *Table 1* illustrates the characteristics of the study population. Among the 468,629 studied participants, 103,384 (22.1%) did not consume coffee on a regular basis, 274,088 (58.5%) consumed 0.5-3 cups per day and 91,157 (19.5%) >3 cups per day.

The association of regular coffee intake with cardiovascular outcomes and all-cause mortality

Median follow-up time was 11 (10-12) years. All-cause and CV mortality rates significantly differed among the various coffee consumption groups (all-cause mortality rate was 3.72%, 3.40% and 4.03% and CV mortality rate was 0.65%, 0.58% and 0.74% in zero, light-to-moderate and high coffee drinkers, respectively; both $p < 0.001$). The univariate analysis showed that light-to-moderate coffee drinking was associated with decreased, while high coffee intake was linked with increased all-cause and CV mortality, as compared to zero coffee drinkers [(HR of all-cause mortality 0.91 (95%CI=0.88-0.95) for light-to-moderate and 1.08 (95%CI=1.04-1.13) for high coffee drinkers and HR for CV mortality 0.89 (95%CI=0.82-0.98) for light-to-moderate and 1.14 (95%CI=1.03-1.27) for high coffee consumers, respectively; all $p < 0.001$].

After adjustment for the potential confounders and mediators, 0.5-3 cups/day proved to be associated with decreased all-cause [(HR=0.88 (95%CI=0.83-0.92), $p < 0.001$)] and CV mortality [(HR=0.83 (95%CI=0.74-0.94) $p = 0.006$)] and lower stroke incidence [(HR=0.79 (95%CI=0.63-0.99), $p = 0.037$)]. Moreover, drinking >3 cups per day was associated with increased risk of incident myocardial infarction [(incidence of myocardial infarction was 0.16% in zero and 0.22% in high coffee drinkers; univariable HR=1.31 (95%CI=1.07-1.61), $p = 0.009$)].

However, this association was not significant after adjustment for potential confounders.

Detailed results of the uni- and multivariable Cox proportional hazard regression analyses are

1 reported in *Table 2*. Kaplan-Meier curves of all-cause mortality by coffee consumption
2 categories are shown in *Figure 1*.
3
4

5 **The association between daily coffee intake and measures of arterial stiffness**

6

7
8 ASI was measured in 139,727 participants at baseline visit. In the univariate analysis both light-
9 to-moderate and high coffee consuming categories were associated with increased ASI [$\beta=0.06$
10 (95%CI=0.01-0.11), $p=0.017$ in light-to-moderate and $\beta=0.26$ (95%CI=0.20-0.33), $p<0.001$ in
11 high coffee drinkers)]. After adjustment for all potential confounders and mediators drinking
12 0.5-3 cups of coffee per day was linked with significantly decreased ASI [$\beta=-0.12$ (95%CI=-
13 0.18 to -0.06), $p<0.001$)]. Data of the association between regular coffee intake and measured
14 arterial stiffness can be seen in *Table 3*.
15
16
17
18
19
20
21
22
23
24

25 **The association of regular coffee consumption with cardiac structure and function**

26

27
28 In order to evaluate the possible underlying mechanisms of the observed association between
29 regular coffee consumption and health outcomes, CMR data of 30,650 participants were
30 analyzed after exclusion. Baseline characteristics of those with and without CMR examination
31 can be seen in *Supplementary table 2*. In the univariable analysis significantly increased
32 LVEDV, LVESV, LVSV, LVM, RVEDV, RVESV and RVSV were found both in light-to-
33 moderate and high coffee intake categories as compared to zero coffee intake, while both LV
34 and RV ejection fractions were reduced in high coffee consuming participants. After adjusting
35 for potential confounders compared to non-coffee drinkers, both the light-to-moderate and high
36 coffee consuming categories, were associated with dose-dependent increased LV and RV
37 ventricular end-diastolic [$\beta=2.21$ (95%CI=1.35-3.08) and $\beta=3.28$ (95%CI=2.18-4.37) for LV
38 and $\beta=2.24$ (95%CI=1.33-3.16) and $\beta=3.35$ (95%CI=2.20-4.50) for RV in light-to-moderate
39 and high coffee drinkers, respectively; all $p<0.001$], end-systolic [$\beta=0.91$ (95%CI=0.39-1.42)
40 and $\beta=1.64$ (95%CI=0.99-2.30) for LV and $\beta=1.10$ (95%CI=0.56-1.64) and $\beta=1.72$
41 (95%CI=1.04-2.41) for RV; all $p<0.001$], and stroke volumes [$\beta=1.31$ (95%CI=0.77-1.85)
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 and $\beta=1.64$ (95%CI=0.95-2.32) for LV and $\beta=1.15$ (95%CI=0.59-1.71) and $\beta=1.63$
2 (95%CI=0.92-2.33) for RV; all $p<0.001$], as well as greater LV mass [$\beta=0.78$ (95%CI=0.30-
3 1.26) and $\beta=1.64$ (95%CI=1.03-2.25); both $p<0.001$]. Detailed data can be seen in *Table 4* and
4
5
6
7 *Figure 2*.

11 **The impact of coffee type on cardiovascular system**

12
13
14
15
16 We additionally explored potential differential impact from different coffee type consumed.
17
18 We compared the differences between the various coffee types, as compared to zero coffee
19 consumption category. Among those who drank coffee regularly, 71,404 (19.5%) participants
20 preferred decaffeinated coffee, 85,120 (23.3%) ground, 201,232 (55.1%) instant and 7,489
21 (2.1%) indicated other coffee type. After adjustment for ~~amount of daily coffee intake and~~ all
22 potential confounders and mediators, decaffeinated coffee was associated with decreased all-
23 cause ~~and CV~~ mortality [HR=0.84 (95%CI=0.75-0.94), p=0.001 for light-to-moderate and
24 HR=0.83 (95%CI=0.70-0.97), p=0.022 for high decaffeinated coffee consumers], 0.5-3 cups of
25 ground coffee per day was linked with decreased all-cause [HR=0.75 (95%CI=0.68-0.83),
26 p<0.001] and CV mortality [HR=0.75 (95%CI=0.59-0.96), p=0.025], and high daily ground
27 coffee intake was associated with lower CV mortality [HR=0.51 (95%CI=0.30-0.81),
28 p=0.008]as well as with decreased incident stroke, while instant coffee type was associated with
29 ~~decreased all-cause mortality but increased risk of incident angina~~. When analyzing the
30 underlying mechanisms in the CMR population, light-to-moderate decaffeinated coffee intake
31 was linked with significantly higher LVEDV [$\beta=2.00$ (95%CI=0.26-3.73), p=0.024], ~~LVESV~~
32 ~~and~~ LVSV [$\beta=1.31$ (95%CI=0.22-2.39), p=0.018], while high amount of daily decaffeinated
33 coffee consumption was associated with significantly greater LVM [$\beta=1.49$ (95%CI=0.09-
34 2.89), p=0.037]. ~~and~~ Ground coffee was associated with increased LVEDV [$\beta=3.99$
35 (95%CI=2.36-5.62) for light-to-moderate and $\beta=6.44$ (95%CI=3.60-9.27) for high intake, both

1 p<0.001], LVESV [$\beta=1.24$ (95%CI=0.25-2.24), p=0.015 for light-to-moderate and $\beta=2.29$
2 (95%CI=0.56-4.03), p=0.010 for high intake], LVSV [$\beta=2.75$ (95%CI=1.76-3.74) for light-to-
3 moderate and $\beta=4.14$ (95%CI=2.41-5.87) for high intake, both p<0.001], RVEDV [$\beta=4.48$
4 (95%CI=2.78-6.18) for light-to-moderate and $\beta=7.43$ (95%CI=4.47-10.40) for high intake,
5 both p<0.001], RVEDV [$\beta=1.88$ (95%CI=0.86-2.91) for light-to-moderate and $\beta=3.80$
6 (95%CI=2.01-5.59) for high intake, both p<0.001] and RVSV [$\beta=2.60$ (95%CI=1.58-3.61) for
7 light-to-moderate and $\beta=3.63$ (95%CI=1.86-5.41) for high intake, both p<0.001] as well as with
8 greater LVM [$\beta=1.74$ (95%CI=0.86-2.63) for light-to-moderate and $\beta=3.33$ (95%CI=1.79-
9 4.88) for high intake, both p<0.001] as compared to zero coffee consumption in the fully
10 adjusted model. Detailed data on the outcome and CMR parameters are reported in
11 *Supplementary tables 3 and 4.*
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Discussion

1
2 In this large cross-sectional population study of 468,629 individuals free from clinical
3
4 cardiovascular disease, light-to-moderate coffee consumption was associated with decreased
5
6 all-cause and CV mortality, and incident stroke. In comparison to zero coffee intake, light-
7
8 moderate and high coffee consumption was also associated with favorable cardiovascular
9
10 phenotypes, both in terms of cardiac and arterial health. Importantly, these associations
11
12 remained robust to adjustment for cardiometabolic morbidities (hypertension, high cholesterol,
13
14 diabetes).

Comparison with other studies

15
16
17
18
19 Coffee is among the most widely consumed pharmacologically active beverages in the world.
20
21 In our study population, 77.9% consumed coffee daily. The CV effects of coffee consumption
22
23 are a combination of favorable and unfavorable effects of caffeine and other drink components.
24
25 Caffeine is by far the most studied compound of coffee. While caffeine has inotropic effect on
26
27 the heart, induces high blood pressure, increases cholesterol level in Nordic countries but not
28
29 in other populations, regular coffee intake was also associated with lower risk of type 2 diabetes
30
31 mellitus, lower body weight and decreased platelet aggregation, inhibition of inflammation (28-
32
33 33). While coffee consumption has been associated with an acute increase in blood pressure in
34
35 caffeine-naive individuals, this effect is negligible in habitual coffee drinkers, and many further
36
37 studies came to the conclusion that long-term coffee consumption has no clinical importance
38
39 on the risk of hypertension (34-36). In line with these findings, the prevalence of hypertension
40
41 was not higher in those drinking >3 cups of coffee per day as compared to zero coffee drinkers
42
43 in the present study. Moreover, in a subpopulation of 139,727 participants who underwent
44
45 arterial stiffness measurement at baseline visit, light-to-moderate coffee consumption was
46
47 associated with lower ASI, an indicator of arterial health and strong correlate of hypertension
48
49 and ischemic cardiovascular risk.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Antioxidants in coffee have been reported to improve glucose metabolism and insulin
2 sensitivity (37). Another study concluded that consumption of more than 5 cups of coffee per
3 day increases adiponectin levels, and decrease insulin resistance (38). In our study population
4 prevalence of diabetes mellitus was significantly lower in light-to-moderate coffee drinkers as
5 compared to zero coffee intake, and similar in high and zero coffee consuming categories.
6
7 Interestingly, we did not observe a significant attenuation of associations with additional
8 adjustment for diabetes, suggesting that associations reported in the present studies are
9 mediated by alternative processes.
10

11 Several previous studies aimed to investigate the effect of regular coffee consumption on CV
12 health. In a prospective study of two Spanish cohorts, 1-7 cups of caffeinated coffee per week
13 was associated with lower risk of atrial fibrillation (39). Moreover, in an umbrella review of
14 201 meta-analyses, coffee consumption was more often linked with beneficial than harmful
15 health outcomes including lower all-cause and CV mortality with the largest relative risk
16 reduction for those consuming 3 to 4 cups/day versus zero (40). Consistent with these findings,
17 in our study light-to-moderate coffee consumption defined as 0.5-3 cups per day was associated
18 with lower risk of all-cause and CV mortality, as compared to zero coffee drinkers. This
19 favorable effect might be partly explained by lower arterial stiffness measures as well as by
20 significantly increased stroke volume in both cardiac ventricles.
21

22 **Clinical competencies and translational outlook**

23 The UK Biobank offers a unique opportunity for the assessment of the potential differences
24 between consumed coffee types. In our study population, ground and instant coffee were the
25 two most commonly taken types. While ground coffee was associated with decreased all-cause
26 and CV mortality ~~and incident stroke~~, we did not find statistically significant association
27 between the association of regular instant coffee consumption ~~with and~~ health outcomes. was
28 controversial, as it was linked with decreased all-cause mortality but increase of incident
29

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

angina. The difference among the various coffee types may be explained by the differences in their production process, as they contain different chemicals. In a recent study of 508,747 participants in the Norwegian cardiovascular surveys, unfiltered brew was linked with higher mortality than filtered brew. Filtered brew was associated with lower mortality than no coffee consumption (41). Interestingly, in our study population regularly consuming decaffeinated coffee was significantly linked with lower all-cause ~~and CV~~ mortality as compared to zero coffee drinkers, suggesting that the observed associations can be explained only partly by caffeine itself. However, further studies with more detailed information on consumed coffee type and preparation are needed to explain the underlying mechanisms.

Strengths and limitations of this study

The main strengths of our study are firstly, the large cohort of asymptomatic population with no prevalent CV disease where prospectively collected data, physical measurements and biological samples are available. Secondly, we used CMR which provides the most accurate and reproducible imaging modality in the assessment of cardiac structure and function. Our study's limitations are important to be acknowledged. First, data regarding coffee consumption was assessed by questionnaires, therefore recall bias may lead to inaccuracy. Furthermore, the single snapshot of coffee consumption habits registered by UK Biobank might not accurately reflect the total lifetime coffee consumption, especially in older people. The observed dose-response relationship between the amount of regular coffee consumption and cardiac changes indicates favorable effects on an epidemiological level despite the observed small effect sizes. Moreover, data regarding strength or size of the consumed coffee were not obtained from the participants, as questionnaire contained only data on cups of daily coffee intake and type of usually consumed coffee. Therefore, we could not calculate the caffeine content. In our study population, there were significant differences between the coffee consuming categories in many

1 dietary, sociological and lifestyle aspects, therefore the possibility that coffee consumption may
2 be acting as a surrogate marker of some other CV risk factor cannot be fully excluded.
3

4 **Conclusions**

5
6
7 To our knowledge, this is the biggest study to systematically assess the CV effects of regular
8 coffee consumption in a large asymptomatic population. Our results suggest that regular coffee
9 consumption is safe, as even high daily coffee intake was not associated with adverse
10 cardiovascular outcomes and all-cause mortality after a follow-up duration of 10 to 15 years.
11
12 Moreover, 0.5-3 cups of coffee per day was independently associated with lower risk of all-
13 cause and CV mortality, and incident stroke. This favorable impact might be partly explained
14
15 by lower ASI and subclinical beneficial alterations in cardiac structure and function.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgement

This study was conducted using the UK Biobank resource under access application 2964.

Authors' contribution

JS, KF, ZRE, NA, SEP and PMH contributed to the conception or design of the work. JS contributed to the acquisition, analysis, or interpretation of data for the work. JS drafted the manuscript. KF, ZRE, NA, SEP and PMH critically revised the manuscript. All gave final approval and agree to be accountable for all aspects of work ensuring integrity and accuracy.

Funding

P.B.M and S.E.P acknowledge support from the National Institute for Health Research (NIHR) Barts Biomedical Research Centre. S.E.P. acknowledges support from the 'SmartHeart' EPSRC programme grant (www.nihr.ac.uk; EP/P001009/1) and also from the CAP-AI programme, London's first AI enabling programme focused on stimulating growth in the capital's AI Sector. CAP-AI is led by Capital Enterprise in partnership with Barts Health NHS Trust and Digital Catapult and is funded by the European Regional Development Fund and Barts Charity. S.E.P. and S.N. acknowledge the British Heart Foundation for funding the manual analysis to create a cardiovascular magnetic resonance imaging reference standard for the UK Biobank imaging resource in 5000 CMR scans (www.bhf.org.uk; PG/14/89/31194). S.N and SKP supported by the Oxford NIHR Biomedical Research Centre and S.N. by the Oxford British Heart Foundation Centre of Research Excellence. N.A. recognize the National Institute for Health Research (NIHR) Integrated Academic Training programme which supports their Academic Clinical Lectureship posts. N.C.H acknowledges support from the UK Medical Research Council (MRC #405050259 and #U105960371), NIHR Southampton Biomedical Research Centre, University of Southampton, and University Hospital Southampton. Z.R.E was supported by a British Heart Foundation Clinical Research Training Fellowship (FS/17/81/33318). Project no. NVKP_16-1-2016-0017 ('National Heart Program') has been

1 implemented with the support provided from the National Research, Development and
2 Innovation Fund of Hungary, financed under the NVKP_16 funding scheme. The research was
3
4 financed by the Thematic Excellence Programme (2020-4.1.1.-TKP2020) of the Ministry for
5
6 Innovation and Technology in Hungary, within the framework of the Therapeutic Development
7
8 and Bioimaging thematic programmes of the Semmelweis University.
9
10

11 12 13 **References** 14 15


- 16 1. Ferruzzi MG. The influence of beverage composition on delivery of phenolic
17 compounds from coffee and tea. *Physiol Behav.* 2010;100(1):33-41.
- 18 2. Zhao CN, Tang GY, Cao SY, Xu XY, Gan RY, Liu Q, et al. Phenolic Profiles and
19 Antioxidant Activities of 30 Tea Infusions from Green, Black, Oolong, White, Yellow and
20 Dark Teas. *Antioxidants (Basel).* 2019;8(7).
- 21 3. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and
22 tea drinking and the risk of late-life dementia: a population-based CAIDE study. *J Alzheimers*
23 *Dis.* 2009;16(1):85-91.
- 24 4. Hu G, Bidel S, Jousilahti P, Antikainen R, Tuomilehto J. Coffee and tea consumption
25 and the risk of Parkinson's disease. *Mov Disord.* 2007;22(15):2242-8.
- 26 5. Odegaard AO, Pereira MA, Koh WP, Arakawa K, Lee HP, Yu MC. Coffee, tea, and
27 incident type 2 diabetes: the Singapore Chinese Health Study. *Am J Clin Nutr.*
28 2008;88(4):979-85.
- 29 6. Sun CL, Yuan JM, Koh WP, Yu MC. Green tea, black tea and breast cancer risk: a
30 meta-analysis of epidemiological studies. *Carcinogenesis.* 2006;27(7):1310-5.
- 31 7. van Dam RM. Coffee consumption and risk of type 2 diabetes, cardiovascular
32 diseases, and cancer. *Appl Physiol Nutr Metab.* 2008;33(6):1269-83.
- 33 8. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee
34 drinking with total and cause-specific mortality. *N Engl J Med.* 2012;366(20):1891-904.
- 35 9. Kleemola P, Jousilahti P, Pietinen P, Vartiainen E, Tuomilehto J. Coffee consumption
36 and the risk of coronary heart disease and death. *Arch Intern Med.* 2000;160(22):3393-400.
- 37 10. LeGrady D, Dyer AR, Shekelle RB, Stamler J, Liu K, Paul O, et al. Coffee
38 consumption and mortality in the Chicago Western Electric Company Study. *Am J*
39 *Epidemiol.* 1987;126(5):803-12.
- 40 11. Mineharu Y, Koizumi A, Wada Y, Iso H, Watanabe Y, Date C, et al. Coffee, green
41 tea, black tea and oolong tea consumption and risk of mortality from cardiovascular disease in
42 Japanese men and women. *J Epidemiol Community Health.* 2011;65(3):230-40.
- 43 12. Woodward M, Tunstall-Pedoe H. Coffee and tea consumption in the Scottish Heart
44 Health Study follow up: conflicting relations with coronary risk factors, coronary disease, and
45 all cause mortality. *J Epidemiol Community Health.* 1999;53(8):481-7.
- 46 13. Niseteo T, Komes D, Belščak-Cvitanović A, Horžić D, Budeč M. Bioactive
47 composition and antioxidant potential of different commonly consumed coffee brews affected
48 by their preparation technique and milk addition. *Food Chem.* 2012;134(4):1870-7.
- 49 14. Mojska H, Gielecińska I. Studies of acrylamide level in coffee and coffee substitutes:
50 influence of raw material and manufacturing conditions. *Rocz Panstw Zakl Hig.*
51 2013;64(3):173-81.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

15. Tran KT, Coleman HG, McMenamin UC, Cardwell CR. Coffee consumption by type and risk of digestive cancer: a large prospective cohort study. *Br J Cancer*. 2019;120(11):1059-66.
16. Creed JH, Smith-Warner SA, Gerke TA, Egan KM. A prospective study of coffee and tea consumption and the risk of glioma in the UK Biobank. *Eur J Cancer*. 2020;129:123-31.
17. Lai GY, Weinstein SJ, Albanes D, Taylor PR, McGlynn KA, Virtamo J, et al. The association of coffee intake with liver cancer incidence and chronic liver disease mortality in male smokers. *Br J Cancer*. 2013;109(5):1344-51.
18. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12(3):e1001779.
19. Said MA, Eppinga RN, Lipsic E, Verweij N, van der Harst P. Relationship of Arterial Stiffness Index and Pulse Pressure With Cardiovascular Disease and Mortality. *J Am Heart Assoc*. 2018;7(2).
20. Petersen SE, Matthews PM, Bamberg F, Bluemke DA, Francis JM, Friedrich MG, et al. Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank - rationale, challenges and approaches. *J Cardiovasc Magn Reson*. 2013;15:46.
21. Petersen SE, Matthews PM, Francis JM, Robson MD, Zemrak F, Boubertakh R, et al. UK Biobank's cardiovascular magnetic resonance protocol. *J Cardiovasc Magn Reson*. 2016;18:8.
22. Petersen SE, Aung N, Sanghvi MM, Zemrak F, Fung K, Paiva JM, et al. Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. *J Cardiovasc Magn Reson*. 2017;19(1):18.
23. Bai W, Sinclair M, Tarroni G, Oktay O, Rajchl M, Vaillant G, et al. Automated cardiovascular magnetic resonance image analysis with fully convolutional networks. *J Cardiovasc Magn Reson*. 2018;20(1):65.
24. Ulvik A, Vollset SE, Hoff G, Ueland PM. Coffee consumption and circulating B-vitamins in healthy middle-aged men and women. *Clin Chem*. 2008;54(9):1489-96.
25. Petersen SE, Sanghvi MM, Aung N, Cooper JA, Paiva JM, Zemrak F, et al. The impact of cardiovascular risk factors on cardiac structure and function: Insights from the UK Biobank imaging enhancement study. *PLoS One*. 2017;12(10):e0185114.
26. Doherty A, Jackson D, Hammerla N, Plotz T, Olivier P, Granat MH, et al. Large Scale Population Assessment of Physical Activity Using Wrist Worn Accelerometers: The UK Biobank Study. *PLoS One*. 2017;12(2):e0169649.
27. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2016;<https://www.r-project.org/>.
28. D'Avanzo B, Santoro L, Nobill A, La Vecchia C. Coffee consumption and serum cholesterol. GISSI-EFRIM Study Group. *Prev Med*. 1993;22(2):219-24.
29. Huxley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, et al. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: a systematic review with meta-analysis. *Arch Intern Med*. 2009;169(22):2053-63.
30. James JE. Is habitual caffeine use a preventable cardiovascular risk factor? *Lancet*. 1997;349(9047):279-81.
31. Kempf K, Herder C, Erlund I, Kolb H, Martin S, Carstensen M, et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. *Am J Clin Nutr*. 2010;91(4):950-7.
32. Paganini-Hill A, Kawas CH, Corrada MM. Non-alcoholic beverage and caffeine consumption and mortality: the Leisure World Cohort Study. *Prev Med*. 2007;44(4):305-10.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
33. Thelle DS, Arnesen E, Forde OH. The Tromso heart study. Does coffee raise serum cholesterol? *N Engl J Med.* 1983;308(24):1454-7.
 34. Mesas AE, Leon-Muñoz LM, Rodriguez-Artalejo F, Lopez-Garcia E. The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. *Am J Clin Nutr.* 2011;94(4):1113-26.
 35. Robertson D, Wade D, Workman R, Woosley RL, Oates JA. Tolerance to the humoral and hemodynamic effects of caffeine in man. *J Clin Invest.* 1981;67(4):1111-7.
 36. Winkelmayr WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. *JAMA.* 2005;294(18):2330-5.
 37. van Dam RM. Coffee and type 2 diabetes: from beans to beta-cells. *Nutr Metab Cardiovasc Dis.* 2006;16(1):69-77.
 38. Wedick NM, Brennan AM, Sun Q, Hu FB, Mantzoros CS, van Dam RM. Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. *Nutr J.* 2011;10:93.
 39. Bazal P, Gea A, Navarro AM, Salas-Salvado J, Corella D, Alonso-Gomez A, et al. Caffeinated coffee consumption and risk of atrial fibrillation in two Spanish cohorts. *Eur J Prev Cardiol.* 2021;28(6):648-57.
 40. Poole R, Kennedy OJ, Roderick P, Fallowfield JA, Hayes PC, Parkes J. Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes. *BMJ.* 2017;359:j5024.
 41. Tverdal A, Selmer R, Cohen JM, Thelle DS. Coffee consumption and mortality from cardiovascular diseases and total mortality: Does the brewing method matter? *Eur J Prev Cardiol.* 2020;27(18):1986-93.


Figure legends

Central illustration




	2	4	6	8	10	All events
zero coffee (n=103,384)	464	1,249	2,151	3,203	3,814	3,844
0.5-3 cups (n=274,088)	1,092	2,921	5,173	7,782	9,250	9,333
>3 cups (n=91,157)	417	1,089	1,988	3,024	3,634	3,671

Figure 1. Kaplan-Meier curve of all-cause mortality as stratified by coffee consumption categories



	2	4	6	8	10	All events
zero coffee (n=103,384)	464	1,249	2,151	3,203	3,814	3,844
0.5-3 cups (n=274,088)	1,092	2,921	5,173	7,782	9,250	9,333
>3 cups (n=91,157)	417	1,089	1,988	3,024	3,634	3,671

Figure 2. Distribution of left and right ventricular structural and functional parameters with light-to-moderate (turquoise) and high (orange) daily coffee consumption as compared to no coffee consumption (gray).



Abbreviations: LVEDV=Left ventricular end-diastolic volume; LVESV= Left ventricular end-systolic volume; LVM=Left ventricular mass; LVSFV=Left ventricular stroke volume; RVEDV=Right ventricular end-diastolic volume; RVESV=Right ventricular end-systolic volume; RVSFV=Right ventricular stroke volume.

Table 1. Participant characteristics

	All participants (n=468,629)	Zero cup of coffee/day (n=103,384)	0.5-3 cups of coffee/day (n=274,088)	>3 cups of coffee/day (n=91,157)	p
Age (years)	56.2±8.1	55.1±8.2	56.8±8.0	55.9±8.0	<0.001
Male, n (%)	207,137 (44.2)	41,504 (40.1)	119,767 (43.7)	45,866 (50.3)	<0.001
Non-European ethnicities, n (%)	24,923 (5.3)	10,156 (9.9)	12,901 (4.7)	1866 (2.1)	<0.001
Townsend deprivation index	-1.24±3.06	-0.92±3.24	-1.50±2.98	-1.39±3.03	<0.001
BMI (kg/m²)	27.3±4.8	27.4±5.0	27.1±4.6	27.9±4.8	<0.001
Hypertension, n (%)	119,129 (25.4)	27,083 (26.2)	69,776 (25.5)	22,270 (24.4)	<0.001
Diabetes mellitus, n (%)	21,084 (4.5)	5,077 (4.9)	11,640 (4.3)	4,367 (4.8)	<0.001
Total cholesterol level (mmol/L)	5.8±1.1	5.7±1.1	5.8±1.1	5.7±1.1	<0.001
IPAQ (METs/week)	1,382 (655- 2,586)	1,386 (622- 2,755)	1,384 (685- 2,550)	1,351 (610- 2,622)	<0.001
Regular fruit intake (portions/day)	2 (1-3)	2 (1-3)	2 (1-3)	2 (1-3)	0.856
Regular raw vegetable intake (portions/day)	2 (1-3)	2 (1-3)	2 (1-3)	2 (1-3)	0.763
Regular cooked vegetable intake (portions/day)	3 (2-3)	2 (2-3)	3 (2-3)	3 (2-3)	0.468
Regular tea intake (cups/day)	3 (1-5)	4 (2-6)	3 (2-5)	1 (0-3)	<0.001
Eating meat at least once a week, n (%)	280,023 (59.8)	58,979 (57.2)	163,028 (59.6)	58,016 (63.8)	<0.001
Drinking alcohol at least once a month, n (%)	378,593 (80.8)	72,282 (70.0)	230,828 (84.3)	75,483 (82.9)	

Previous or current smoker, n (%)	206,535 (44.1)	41,192 (40.0)	117,099 (42.9)	48,244 (43.1)	<0.001
Types of most commonly consumed coffee					<0.001
Decaffeinated, n (%)	71,404 (19.5)	-	53,173 (19.4)	18,231 (20.0)	
Ground, n (%)	85,120 (23.3)	-	71,811 (26.2)	13,309 (14.6)	
Instant, n (%)	201,232 (55.1)	-	143,074 (52.2)	58,158 (63.8)	
Other, n (%)	7,489 (2.1)	-	6,030 (2.2)	1,459 (1.6)	

Summary statistics for independent variables were calculated as means and standard deviation (SD) or median and interquartile range (IQR) for continuous variables or case numbers and percentages for categorical variables

Abbreviations: BMI=body mass index; IPAQ=international physical activity questionnaire; METs=metabolic equivalents

Table 2. Association of regular coffee consumption with all-cause and CV mortality, and CV disease incidence as compared with non-coffee drinkers

	Univariable		Confounders (Model 1)		Confounders + mediators (Model 2)	
	HR (95%CI)	p	HR (95%CI)	p	HR (95%CI)	p
All-cause mortality						
0.5-3 cups	0.91 (0.88-0.95)	<0.001	0.87 (0.83-0.91)	<0.001	0.88 (0.83-0.92)	<0.001
>3 cups	1.08 (1.04-1.13)	<0.001	0.99 (0.93-1.05)	0.641	1.00 (0.94-1.07)	0.955
CV mortality						
0.5-3 cups	0.89 (0.82-0.98)	0.014	0.85 (0.76-0.95)	0.005	0.83 (0.74-0.94)	0.006
>3 cups	1.14 (1.03-1.27)	0.015	0.98 (0.85-1.13)	0.768	0.98 (0.85-1.13)	0.786
Incidental stroke						
0.5-3 cups	0.91 (0.76-1.08)	0.277	0.82 (0.66-1.02)	0.071	0.79 (0.63-0.99)	0.037
>3 cups	1.03 (0.84-1.28)	0.763	0.97 (0.74-1.27)	0.797	0.98 (0.74-1.29)	0.873
Incidental heart attack						
0.5-3 cups	1.01 (0.85-1.20)	0.938	0.99 (0.79-1.22)	0.897	0.96 (0.77-1.20)	0.733
>3 cups	1.31 (1.07-1.61)	0.009	1.15 (0.89-1.49)	0.274	1.10 (0.85-1.43)	0.466

Abbreviations: CI=Confidence interval; CV=Cardiovascular; HR=Hazard ratio.

Confounders: (baseline) age, sex, non-European ethnicities, body mass index, smoking, physical activity, Townsend deprivation index, alcohol, meat, tea, fruit and vegetable intake.

Mediators: (baseline) hypertension, diabetes mellitus, cholesterol level.

Table 3. Association between regular coffee consumption and ASI as compared to non-coffee drinkers

	Mean ± SD	Univariate		Confounders		Confounders + mediators	
		β (95% CI)	p	β (95% CI)	p	β (95% CI)	p
ASI							
0.5-3 cups	9.27± 3.65	0.06 (0.01- 0.11)	0.017	-0.10 (-0.16- 0.00)	<0.001	-0.12 (-0.18 to -0.06)	<0.001
>3 cups	9.48± 3.50	0.26 (0.20- 0.33)	<0.001	0.01 (-0.07- 0.09)	0.775	-0.01 (-0.07- 0.09)	0.821

Confounders: (baseline) age, sex, non-European ethnicities, body mass index, smoking, physical activity, Townsend deprivation index, alcohol, meat, tea, fruit and vegetable intake.

Mediators: (baseline) hypertension, diabetes mellitus, cholesterol level.

Abbreviations: ASI=Arterial stiffness index.

Table 4. Association between regular coffee consumption and cardiac structural and functional parameters

	Mean±SD	Univariable		Confounders		Confounders + mediators	
		β (95% CI)	p	β (95% CI)	p	β (95% CI)	p
LVEDV (ml)							
zero coffee	144.3±33.0	Ref		Ref		Ref	
0.5-3 cups/day	147.3±33.3	3.01 (2.04-3.97)	<0.001	2.13 (1.28-2.97)	<0.001	2.21 (1.35-3.08)	<0.001
>3 cups/day	152.5±34.2	8.22 (7.04-9.39)	<0.001	3.08 (2.02-4.15)	<0.001	3.28 (2.18-4.37)	<0.001
LVESV (ml)							
zero coffee	58.6±18.7	Ref		Ref		Ref	
0.5-3 cups/day	60.0±18.8	1.44 (0.90-1.98)	<0.001	0.85 (0.35-1.35)	<0.001	0.91 (0.39-1.42)	<0.001
>3 cups/day	62.8±19.5	4.17 (3.51-4.84)	<0.001	1.56 (0.93-2.20)	<0.001	1.64 (0.99-2.30)	<0.001
LVSV (ml)							
zero coffee	85.7±18.9	Ref		Ref		Ref	
0.5-3 cups/day	87.2±19.1	1.57 (1.01-2.12)	<0.001	1.27 (0.74-1.80)	<0.001	1.31 (0.77-1.85)	<0.001
>3 cups/day	89.7±19.5	4.04 (3.37-4.72)	<0.001	1.52 (8.54-2.19)	<0.001	1.64 (0.95-2.32)	<0.001
LVEF (%)							
zero coffee	59.8±5.9	Ref		Ref		Ref	
0.5-3 cups/day	59.5±6.0	-0.16 (-0.33-0.01)	0.070	-0.03 (-0.21-0.16)	0.795	-0.03 (-0.23-0.16)	0.705
>3 cups/day	59.2±6.1	-0.55 (-0.76 to -0.33)	<0.001	-0.20 (-0.43-0.04)	0.108	-0.21 (-0.45-0.04)	0.100
LVM (g)							
zero coffee	83.5±21.9	Ref		Ref		Ref	
0.5-3 cups/day	85.7±22.0	2.20 (1.56-2.84)	<0.001	0.77 (0.30-1.24)	0.001	0.78 (0.30-1.26)	0.001

>3 cups/day	90.3±23.3	6.84 (6.06-7.62)	<0.001	1.57 (0.98-2.16)	<0.001	1.64 (1.03-2.25)	<0.001
RVEDV (ml)							
zero coffee	152.4±36.8	Ref		Ref		Ref	
0.5-3 cups/day	155.9±36.8	3.48 (2.41-4.55)	<0.001	2.19 (1.30-3.08)	<0.001	2.24 (1.33-3.16)	<0.001
>3 cups/day	161.7±38.2	9.23 (7.93-10.54)	<0.001	3.17 (2.04-4.29)	<0.001	3.35 (2.20-4.50)	<0.001
RVESV (ml)							
zero coffee	65.6±21.1	Ref		Ref		Ref	
0.5-3 cups/day	67.3±21.2	1.71 (1.10-2.32)	<0.001	1.06 (0.54-1.59)	0.001	1.10 (0.56-1.64)	<0.001
>3 cups/day	70.4±21.8	4.83 (4.08-5.57)	<0.001	1.63 (0.97-2.30)	<0.001	1.72 (1.04-2.41)	<0.001
RVSV (ml)							
zero coffee	86.8±19.8	Ref		Ref		Ref	
0.5-3 cups/day	88.6±20.0	1.78 (1.20-2.36)	<0.001	1.13 (0.58-1.67)	<0.001	1.15 (0.59-1.71)	<0.001
>3 cups/day	91.3±20.8	4.41 (3.70-5.12)	<0.001	1.53 (0.84-2.23)	<0.001	1.63 (0.92-2.33)	<0.001
RVEF (%)							
zero coffee	57.4±6.1	Ref		Ref		Ref	
0.5-3 cups/day	57.3±6.2	-0.16 (-0.33-0.02)	0.082	-0.08 (-0.27-0.10)	0.376	-0.10 (-0.29-0.10)	0.330
>3 cups/day	56.9±6.1	-0.58 (-0.79 to -0.36)	<0.001	-0.17 (-0.41-0.07)	0.164	-0.19 (-0.43-0.06)	0.135

Abbreviations: CI=Confidence interval; LVEDV= Left ventricular end-diastolic volume; LVEF=Left ventricular ejection fraction; LVESV= Left ventricular end-systolic volume; LVM=Left ventricular mass; LVSV=Left ventricular stroke volume; RVEDV=Right ventricular end-diastolic volume; RVEF=Right ventricular ejection fraction; RVESV=Right ventricular end-systolic volume; RVSV=Right ventricular stroke volume.

Confounders: (baseline) age, sex, non-European ethnicities, body mass index, smoking, physical activity, Townsend deprivation index, alcohol, meat, tea, fruit and vegetable intake.

Mediators: (baseline) hypertension, diabetes mellitus, cholesterol level.

Supplementary table 1. Underlying (primary) causes of cardiovascular death

Disease code	Underlying cause of death	n
I10-I15	Hypertensive diseases	-
I10	Essential (primary) hypertension	17
I11	Hypertensive heart disease	83
I12	Hypertensive renal disease	5
I13	Hypertensive heart and renal disease	2
I20-I25	Ischemic heart diseases	-
I21	Acute myocardial infarction	616
I24	Other acute ischemic heart disease	8
I25	Chronic ischemic heart disease	806
I26-I28	Pulmonary heart disease and diseases of pulmonary circulation	-
I26	Pulmonary embolism	84
I27	Other pulmonary heart diseases	17
I28	Other diseases of pulmonary vessels	1
I30-I52	Other forms of heart disease	-
I30	Acute pericarditis	3
I31	Other diseases of the pericardium	13
I33	Acute and subacute endocarditis	13
I34	Nonrheumatic mitral valve disorders	12
I35	Nonrheumatic aortic valve disorders	64
I38	Endocarditis, valve unspecified	16
I40	Acute myocarditis	1
I42	Cardiomyopathy	83
I44	Atrioventricular and left bundle-branch block	2
I45	Other conduction disorders	1
I46	Cardiac arrest	5
I47	Paroxysmal tachycardia	1
I48	Atrial fibrillation and flutter	31
I49	Other cardiac arrhythmias	9
I50	Heart failure	37
I51	Complications and ill-defined descriptions of heart disease	39
I60-I69	Cerebrovascular diseases	-
I60	Subarachnoid haemorrhage	145
I61	Intracerebral haemorrhage	158
I62	Other nontraumatic intracranial haemorrhage	53
I63	Cerebral infarction	69
I64	Stroke, not specified as haemorrhage or infarction	157
I67	Other cerebrovascular diseases	26
I69	Sequelae of cerebrovascular disease	3
I70-I79	Diseases of arteries, arterioles and capillaries	-
I70	Atherosclerosis	3
I71	Aortic aneurysm and dissection	168
I72	Other aneurysm	9
I73	Other peripheral vascular disease, unspecified	16
I74	Arterial embolism and thrombosis	4
I77	Other disorders of arteries and arterioles	8

I80-I89	Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified	-
I80	Phlebitis and thrombophlebitis	126
I81	Portal vein thrombosis	5
I82	Other venous embolism and thrombosis	3
I83	Varicose veins of lower extremities	4
I85	Oesophageal varices	4
I87	Other disorders of veins	1
I89	Other non-infective disorders of lymphatic vessels and lymph nodes	1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Supplementary table 2. Participant characteristics of patients with and without CMR examination

	Patients with no CMR (n=437,693)	CMR population (n=30,650)	p
Age (years)	56.3±8.1	54.7±7.5	<0.001
Male, n (%)	14,460 (44.0)	192,479 (47.2)	<0.001
Non-European ethnicities, n (%)	24,093 (5.5)	822 (2.7)	<0.001
Townsend deprivation index	-1.31±3.08	-1.97±2.66	<0.001
BMI (kg/m²)	27.4±4.8	26.5±4.2	<0.001
Hypertension, n (%)	113,221 (25.4)	5,800 (18.9)	<0.001
Diabetes mellitus, n (%)	20,343 (4.7)	719 (2.3)	<0.001
Total cholesterol level (mmol/L)	5.8±1.1	5.8±1.1	0.712
IPAQ (METs/week)	1,386 (657-2,610)	1,324 (650-2,426)	<0.001
Regular tea intake (cups/day)	3 (1-5)	3 (1-5)	0.618
Eating meat at least once a week, n (%)	261,784 (59.9)	18,053 (58.9)	<0.001
Drinking alcohol at least once a month, n (%)	351,676 (80.4)	26,669 (87.0)	<0.001
Previous or current smoker, n (%)	194,550 (44.6)	11,845 (38.7)	<0.001
Coffee consumption			<0.001
Zero	97,253 (22.2)	6,077 (19.8)	
0.5-3 cups/day	255,549 (58.4)	18,376 (60.0)	
>3 cups/day	84,891 (19.4)	6,197 (20.2)	

Summary statistics for independent variables were calculated as means and SD or median and IQR for continuous variables or frequencies and percentages for categorical variables.

Abbreviations: BMI=body mass index; IPAQ=international physical activity questionnaire; METs=metabolic equivalents.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Supplementary table 3. Multivariable analysis for association of coffee type with cardiovascular outcomes and all-cause mortality

-	<u>Decaffeinated</u>		<u>Ground</u>		<u>Instant</u>		<u>Other</u>	
	<u>HR (95% CI)</u>	<u>p</u>	<u>HR (95% CI)</u>	<u>p</u>	<u>HR (95% CI)</u>	<u>p</u>	<u>HR (95% CI)</u>	<u>p</u>
<u>All-cause mortality</u>								
<u>0.5-3 cups</u>	<u>0.84 (0.75-0.94)</u>	<u>0.001</u>	<u>0.75 (0.68-0.83)</u>	<u><0.001</u>	<u>0.93 (0.86-1.00)</u>	<u>0.055</u>	<u>0.83 (0.63-1.07)</u>	<u>0.167</u>
<u>>3 cups</u>	<u>0.83 (0.70-0.97)</u>	<u>0.022</u>	<u>0.85 (0.71-1.02)</u>	<u>0.078</u>	<u>0.99 (0.89-1.09)</u>	<u>0.821</u>	<u>1.23 (0.73-1.95)</u>	<u>0.404</u>
<u>CV mortality</u>								
<u>0.5-3 cups</u>	<u>0.83 (0.64-1.08)</u>	<u>0.175</u>	<u>0.75 (0.59-0.96)</u>	<u>0.025</u>	<u>0.87 (-0.72-1.05)</u>	<u>0.148</u>	<u>1.10 (0.59-1.88)</u>	<u>0.732</u>
<u>>3 cups</u>	<u>0.84 (0.57-1.21)</u>	<u>0.354</u>	<u>0.51 (0.30-0.81)</u>	<u>0.008</u>	<u>1.13 (-0.90-1.42)</u>	<u>0.286</u>	<u>0.73 (0.12-2.33)</u>	<u>0.661</u>
<u>Incident stroke</u>								
<u>0.5-3 cups</u>	<u>1.08 (0.64-1.79)</u>	<u>0.769</u>	<u>0.68 (0.40-1.16)</u>	<u>0.168</u>	<u>0.95 (0.64-1.43)</u>	<u>0.797</u>	<u>0.00 (0.00-0.00)</u>	<u>0.980</u>
<u>>3 cups</u>	<u>1.21 (0.55-2.44)</u>	<u>0.605</u>	<u>0.31 (0.05-1.05)</u>	<u>0.115</u>	<u>1.22 (0.73-2.01)</u>	<u>0.444</u>	<u>0.00 (0.00-0.00)</u>	<u>0.992</u>
<u>Incident myocardial infarction</u>								
<u>0.5-3 cups</u>	<u>0.72 (0.40-1.23)</u>	<u>0.242</u>	<u>0.99 (0.62-1.57)</u>	<u>0.964</u>	<u>1.04 (0.72-1.53)</u>	<u>0.822</u>	<u>1.82 (0.62-4.22)</u>	<u>0.211</u>
<u>>3 cups</u>	<u>0.63 (0.23-1.44)</u>	<u>0.315</u>	<u>0.86 (0.34-1.84)</u>	<u>0.712</u>	<u>1.30 (0.82-2.06)</u>	<u>0.261</u>	<u>0.00 (0.00-0.00)</u>	<u>0.980</u>

Abbreviations: CI=Confidence interval; CV=Cardiovascular; HR=Hazard ratio.

After adjustment for baseline age, sex, non-European ethnicities, body mass index, smoking, physical activity, Townsend deprivation index, alcohol, meat, tea, fruit and vegetable intake, hypertension, diabetes mellitus, cholesterol level.

Supplementary table 4. Multivariate analysis for association between coffee type and CMR parameters

	<u>Decaffeinated</u>		<u>Ground</u>		<u>Instant</u>		<u>Other</u>	
	<u>β (95% CI)</u>	<u>p</u>	<u>β (95% CI)</u>	<u>p</u>	<u>β (95% CI)</u>	<u>p</u>	<u>β (95% CI)</u>	<u>p</u>
<u>LVEDV (ml)</u>								
<u>0.5-3 cups</u>	<u>2.00 (0.26-3.73)</u>	<u>0.024</u>	<u>3.99 (2.36-5.62)</u>	<u><0.001</u>	<u>0.03 (-1.38-1.43)</u>	<u>0.972</u>	<u>-2.26 (-6.86-2.34)</u>	<u>0.336</u>
<u>>3 cups</u>	<u>2.53 (-0.05-5.11)</u>	<u>0.055</u>	<u>6.44 (3.60-9.27)</u>	<u><0.001</u>	<u>2.09 (0.26-3.92)</u>	<u>0.025</u>	<u>7.98 (-3.29-19.25)</u>	<u>0.165</u>
<u>LVESV (ml)</u>								
<u>0.5-3 cups</u>	<u>0.69 (-0.37-1.76)</u>	<u>0.203</u>	<u>1.24 (0.25-2.24)</u>	<u>0.015</u>	<u>-0.34 (-1.21-0.53)</u>	<u>0.449</u>	<u>-2.21 (-5.10-0.67)</u>	<u>0.133</u>
<u>>3 cups</u>	<u>1.48 (-0.10-3.06)</u>	<u>0.066</u>	<u>2.29 (0.56-4.03)</u>	<u>0.010</u>	<u>1.01 (-0.12-2.14)</u>	<u>0.078</u>	<u>2.94 (-4.12-10.00)</u>	<u>0.414</u>
<u>LVSV (ml)</u>								
<u>0.5-3 cups</u>	<u>1.31 (0.22-2.39)</u>	<u>0.018</u>	<u>2.75 (1.76-3.74)</u>	<u><0.001</u>	<u>0.36 (-0.50-1.22)</u>	<u>0.412</u>	<u>-0.05 (-2.85-2.75)</u>	<u>0.973</u>
<u>>3 cups</u>	<u>1.05 (-0.56-2.65)</u>	<u>0.203</u>	<u>4.14 (2.41-5.87)</u>	<u><0.001</u>	<u>1.08 (-0.04-2.19)</u>	<u>0.059</u>	<u>5.04 (-1.81-11.88)</u>	<u>0.149</u>
<u>LVEF (%)</u>								
<u>0.5-3 cups</u>	<u>-0.03 (-0.43-0.37)</u>	<u>0.892</u>	<u>0.21 (-0.15-0.56)</u>	<u>0.250</u>	<u>0.19 (-0.12-0.50)</u>	<u>0.239</u>	<u>0.70 (-0.32-1.73)</u>	<u>0.177</u>
<u>>3 cups</u>	<u>-0.34 (-0.94-0.24)</u>	<u>0.255</u>	<u>0.21 (-0.41-0.83)</u>	<u>0.511</u>	<u>-0.08 (-0.49-0.32)</u>	<u>0.692</u>	<u>-0.23 (-2.73-2.27)</u>	<u>0.856</u>
<u>LVM (g)</u>								
<u>0.5-3 cups</u>	<u>0.30 (-0.64-1.25)</u>	<u>0.529</u>	<u>1.74 (0.86-2.63)</u>	<u><0.001</u>	<u>0.13 (-0.64-0.91)</u>	<u>0.732</u>	<u>-1.03 (-3.50-1.44)</u>	<u>0.415</u>
<u>>3 cups</u>	<u>1.49 (0.09-2.89)</u>	<u>0.037</u>	<u>3.33 (1.79-4.88)</u>	<u><0.001</u>	<u>1.30 (0.30-2.30)</u>	<u>0.011</u>	<u>4.61 (-1.44-10.66)</u>	<u>0.135</u>
<u>RVEDV (ml)</u>								
<u>0.5-3 cups</u>	<u>1.08 (-0.76-2.91)</u>	<u>0.250</u>	<u>4.48 (2.78-6.18)</u>	<u><0.001</u>	<u>-0.59 (-2.06-0.88)</u>	<u>0.433</u>	<u>-1.47 (-6.34-3.40)</u>	<u>0.553</u>
<u>>3 cups</u>	<u>1.98 (-0.74-4.71)</u>	<u>0.154</u>	<u>7.43 (4.47-10.40)</u>	<u><0.001</u>	<u>1.43 (-0.48-3.33)</u>	<u>0.142</u>	<u>1.13 (-0.66-23.17)</u>	<u>0.064</u>

<u>RVESV (ml)</u>								
<u>0.5-3 cups</u>	<u>0.27 (-0.82-1.36)</u>	<u>0.625</u>	<u>1.88 (0.86-2.91)</u>	<u><0.001</u>	<u>-0.41 (-1.28-0.46)</u>	<u>0.352</u>	<u>-1.54 (-4.48-1.40)</u>	<u>0.305</u>
<u>>3 cups</u>	<u>0.97 (-0.65-2.59)</u>	<u>0.240</u>	<u>3.80 (2.01-5.59)</u>	<u><0.001</u>	<u>0.50 (-0.62-1.62)</u>	<u>0.384</u>	<u>5.78 (-1.41-12.98)</u>	<u>0.115</u>
<u>RVSV (ml)</u>								
<u>0.5-3 cups</u>	<u>0.81 (-0.32-1.93)</u>	<u>0.161</u>	<u>2.60 (1.58-3.61)</u>	<u><0.001</u>	<u>-0.18 (-1.07-0.72)</u>	<u>0.700</u>	<u>0.06 (-2.86-2.99)</u>	<u>0.966</u>
<u>>3 cups</u>	<u>1.01 (-0.66-2.69)</u>	<u>0.267</u>	<u>3.63 (1.86-5.41)</u>	<u><0.001</u>	<u>0.93 (-0.23-2.09)</u>	<u>0.117</u>	<u>5.47 (-1.68-12.62)</u>	<u>0.134</u>
<u>RVEF (%)</u>								
<u>0.5-3 cups</u>	<u>0.05 (-0.35-0.45)</u>	<u>0.810</u>	<u>0.02 (-0.33-0.38)</u>	<u>0.902</u>	<u>0.05 (-0.25-0.36)</u>	<u>0.740</u>	<u>0.63 (-0.41-1.68)</u>	<u>0.234</u>
<u>>3 cups</u>	<u>-0.18 (-0.78-0.41)</u>	<u>0.546</u>	<u>-0.24 (-0.86-0.37)</u>	<u>0.439</u>	<u>-0.01 (-0.41-0.39)</u>	<u>0.957</u>	<u>-0.49 (-3.05-2.06)</u>	<u>0.705</u>

Abbreviations: CI=Confidence interval; LVEDV= Left ventricular end-diastolic volume; LVEF=Left ventricular ejection fraction; LVESV= Left ventricular end-systolic volume; LVM=Left ventricular mass; LVSV=Left ventricular stroke volume; RVEDV=Right ventricular end-diastolic volume; RVEF=Right ventricular ejection fraction; RVESV=Right ventricular end-systolic volume; RVSV=Right ventricular stroke volume.

After adjustment for baseline age, sex, non-European ethnicities, body mass index, smoking, physical activity, Townsend deprivation index, alcohol, meat, tea, fruit and vegetable intake, hypertension, diabetes mellitus, cholesterol level.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65